英文药名: Eliquis(Apixaban Tablets)
中文药名: 阿哌沙班片 药品介绍 由辉瑞与百时美施贵宝联合开发的新药血管稀释剂eliquis(阿哌沙班)已获得了欧洲药品监管机构的批准。早前,该药就受到了各界的广泛关注。据辉瑞表示,该药用于接受过臀部或膝部置换手术患者的血栓预防。 eliquis能预防血栓,但出血的不良反应低于老药华法林,因而被认为是一只具有“重磅炸弹”潜力的药物。 Eliquis(apixaban,阿哌沙班)用于预防中风。针对该药的临床试验取得最佳结果:Eliquis将安全性和有效性完美地结合在一起。 Eliquis(apixaban,阿哌沙班)与现行的标准治疗药物华法林(warfarin)相比,该药令患者发生严重出血的危险性降低31%。引发出血是血液稀释剂令人担忧的一个副作用。此外,使用Eliquis的患者发生死亡的危险性可降低11%,这是华法林替代产品首次在研究中显示可拯救患者生命。 目前在治疗中风的抗凝血的药物中,主要有华法林、Pradaxa、Eliquis(apixaban,阿哌沙班)、Xarelto等药。 批准日期:2012年12月28日;公司:Bristol-Myers Squibb公司和Pfizer Inc. 适应证和用途 ELIQUIS是一种凝血因子Xa的抑制剂抗凝剂适用于在有非瓣膜病房颤患者中减低卒中和全身性栓塞的风险。 剂量和给药方法 (1)推荐剂量是5 mg口服每天2次。 (2)在有至少下列特性之二患者:年龄≥80岁,体重 ≤60kg,或血清肌酐≥1.5mg/dL,推荐剂量为2.5mg口服每天2次。 剂型和规格 片:2.5mg和5mg 禁忌证 (1)活动性病理性出血。 (2)对ELIQUIS (apixaban)严重超敏性。 警告和注意事项 (1)ELIQUIS可致严重,潜在致命性出血。及时评估失血的迹象和症状。 (2)人工心脏瓣膜:不建议使用ELIQUIS。 不良反应 最常见不良反应(>1%)是与出血有关。 为报告怀疑不良反应,连续Bristol-Myers Squibb电话1-800-721-5072或FDA电话1-800-FDA-1088或www.fda.gov/medwatch 药物相互作用 (1)强CYP3A4和P-gp的双重抑制剂增加apixaban的血水平:减低ELIQUIS剂量至2.5mg或避免同时使用。 (2)强CYP3A4和P-gp诱导剂的同时使用减低apixaban的血水平:避免同时使用。 特殊人群中使用 (1)哺乳母亲:终止药物或终止哺乳。 (2)妊娠:不建议使用. (3)严重肝受损:不建议使用。
Eliquis 2.5 mg film-coated tablets Eliquis 5 mg film-coated tablets -------------------------------------------- The following risk minimisation materials have been developed for Eliquis(apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II): •Prescriber Guide – for healthcare professionals •Patient Alert Card – for patients (to be given by the healthcare professional) •Summary of Product Characteristics (SmPC, 5mg and 2.5mg) – for healthcare professionals Please ensure that you are familiar with these educational materials before prescribing Eliquis as they contain important safety information. In particular, they are aimed at increasing awareness about the potential risk of bleeding during treatment with Eliquis and providing guidance on how to manage that risk. Please click on this link to view the materials. ---------------------------------------------------------- Eliquis 2.5 mg film-coated tablets 1. Name of the medicinal product Eliquis 2.5 mg film-coated tablets 2. Qualitative and quantitative composition Each film-coated tablet contains 2.5 mg apixaban. Excipients with known effect: Each 2.5 mg film-coated tablet contains 51.43 mg lactose (see section 4.4). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablet (tablet) Yellow, round tablets debossed with 893 on one side and 2½ on the other side. 4. Clinical particulars 4.1 Therapeutic indications Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). 4.2 Posology and method of administration Posology Prevention of VTE (VTEp): elective hip or knee replacement surgery The recommended dose of Eliquis is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery. Physicians may consider the potential benefits of earlier anticoagulation for VTE prophylaxis as well as the risks of post-surgical bleeding in deciding on the time of administration within this time window. In patients undergoing hip replacement surgery The recommended duration of treatment is 32 to 38 days. In patients undergoing knee replacement surgery The recommended duration of treatment is 10 to 14 days. Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) The recommended dose of Eliquis is 5 mg taken orally twice daily. Dose reduction The recommended dose of Eliquis is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dl (133 micromole/l). Therapy should be continued long term. Missed Dose If a dose is missed, the patient should take Eliquis immediately and then continue with twice daily intake as before. Switching Switching treatment from parenteral anticoagulants to Eliquis (and vice versa) can be done at the next scheduled dose (see section 4.5). Switching from Vitamin K antagonist (VKA) therapy to Eliquis When converting patients from Vitamin K antagonist (VKA) therapy to Eliquis, discontinue warfarin or other VKA therapy and start Eliquis when the international normalized ratio (INR) is < 2.0. Switching from Eliquis to VKA therapy When converting patients from Eliquis to VKA therapy, continue administration of Eliquis for at least 2 days after beginning VKA therapy. After 2 days of coadministration of Eliquis with VKA therapy, obtain an INR prior to the next scheduled dose of Eliquis. Continue coadministration of Eliquis and VKA therapy until the INR is ≥ 2.0. Renal impairment As there is no clinical experience in patients with creatinine clearance < 15 ml/min, or in patients undergoing dialysis, apixaban is not recommended in these patients (see sections 4.4 and 5.2). Prevention of VTE (VTEp): elective hip or knee replacement surgery No dose adjustment is necessary in patients with mild or moderate renal impairment (see section 5.2). Limited clinical data in patients with severe renal impairment (creatinine clearance 15-29 ml/min) indicate that apixaban plasma concentrations are increased in this patient population, therefore, apixaban is to be used with caution in these patients (see sections 4.4 and 5.2). Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) No dose adjustment is necessary in patients with mild or moderate renal impairment (see section 5.2). Patients with serum creatinine ≥ 1.5 mg/dL (133 micromole/l) associated with age ≥ 80 years or body weight ≤ 60 kg should receive the lower dose of apixaban 2.5 mg twice daily. Patients with exclusive criteria of severe renal impairment (creatinine clearance 15-29 ml/min) should also receive the lower dose of apixaban 2.5 mg twice daily. Hepatic impairment Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3). It is not recommended in patients with severe hepatic impairment (see sections 4.4. and 5.2). It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B). No dose adjustment is required in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2). Patients with elevated liver enzymes (ALT/AST >2 x ULN) or total bilirubin ≥1.5 x ULN were excluded in clinical trials. Therefore Eliquis should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating Eliquis, liver function testing should be performed. Body weight VTEp - No dose adjustment required (see section 5.2). NVAF - No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2). Gender No dose adjustment required (see section 5.2). Elderly VTEp – No dose adjustment required (see sections 4.4 and 5.2). NVAF – No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2). Cardioversion (NVAF) Patients can stay on apixaban while being cardioverted. Paediatric population The safety and efficacy of Eliquis in children and adolescents below age 18 have not been established. No data are available. Method of administration Oral use. Eliquis should be swallowed with water, with or without food. 4.3 Contraindications • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. • Active clinically significant bleeding. • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 5.2). • Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. • Concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under the circumstances of switching therapy to or from apixaban (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5). 4.4 Special warnings and precautions for use Haemorrhage risk As with other anticoagulants, patients taking Eliquis are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Eliquis administration should be discontinued if severe haemorrhage occurs (see sections 4.8 and 4.9). Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see section 5.1). Interaction with other medicinal products affecting haemostasis Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3). The concomitant use of Eliquis with antiplatelet agents increases the risk of bleeding (see section 4.5). Care is to be taken if patients are treated concomitantly with non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid. Following surgery, other platelet aggregation inhibitors are not recommended concomitantly with Eliquis (see section 4.5). In patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the potential risks should be made before combining this therapy with Eliquis. In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.1%) use of concomitant dual antiplatelet therapy. In a clinical trial of high-risk post acute coronary syndrome patients, characterized by multiple cardiac and non-cardiac comorbidities, who received ASA or the combination of ASA and clopidogrel, a significant increase in risk of ISTH (International Society on Thrombosis and Haemostasis) major bleeding was reported for apixaban (5.13% per year) compared to placebo (2.04% per year) . Use of Thrombolytic agents for the treatment of acute ischemic stroke There is very limited experience with the use of thrombolytic agents for the treatment of acute ischemic stroke in patients administered apixaban. Patients with prosthetic heart valves Safety and efficacy of Eliquis have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation. Therefore, the use of Eliquis is not recommended in this setting. Surgery and invasive procedures Eliquis should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding. This includes interventions for which the probability of clinically significant bleeding cannot be excluded or for which the risk of bleeding would be unacceptable. Eliquis should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding. This includes interventions for which any bleeding that occurs is expected to be minimal, non-critical in its location or easily controlled. If surgery or invasive procedures cannot be delayed, appropriate caution should be exercised, taking into consideration an increased risk of bleeding. This risk of bleeding should be weighed against the urgency of intervention. Apixaban should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established (for cardioversion see section 4.2). Temporary discontinuation Discontinuing anticoagulants, including Eliquis, for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of thrombosis. Lapses in therapy should be avoided and if anticoagulation with Eliquis must be temporarily discontinued for any reason, therapy should be restarted as soon as possible. Spinal/epidural anaesthesia or puncture When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. Indwelling epidural or intrathecal catheters must be removed at least 5 hours prior to the first dose of Eliquis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of apixaban with indwelling intrathecal or epidural catheters. In case there is such need and based on the general PK characteristics of apixaban, a time interval of 20-30 hours (i.e., 2 x half-life) between the last dose of apixaban and catheter withdrawal should elapse, and at least one dose should be omitted before catheter withdrawal. The next dose of apixaban may be given at least 5 hours after catheter removal. As with all new anticoagulant drugs, experience with neuraxial blockade is limited and extreme caution is therefore recommended when using apixaban in the presence of neuraxial blockade. Renal impairment As there is no clinical experience in patients with creatinine clearance < 15 ml/min, or in patients undergoing dialysis, apixaban is not recommended in these patients (see sections 4.2 and 5.2). Prevention of VTE (VTEp): elective hip or knee replacement surgery No dose adjustment is necessary in patients with mild or moderate renal impairment (see section 5.2). Limited clinical data in patients with severe renal impairment (creatinine clearance 15-29 ml/min) indicate that apixaban plasma concentrations are increased in this patient population, therefore, apixaban alone or in combination with acetylsalicylic acid (ASA) is to be used with caution in these patients because of a potentially higher bleeding risk (see sections 4.2 and 5.2). Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) No dose adjustment is necessary in patients with mild or moderate renal impairment (see section 4.2 and 5.2). Patients with serum creatinine ≥ 1.5 mg/dL (133 micromole/l) associated with age ≥ 80 years or body weight ≤ 60 kg should receive the lower dose of apixaban 2.5 mg twice daily. Patients with exclusive criteria of severe renal impairment (creatinine clearance 15-29 ml/min) should also receive the lower dose of apixaban 2.5 mg twice daily (see section 4.2). Elderly patients The co-administration of Eliquis with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk. Hepatic impairment Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3). It is not recommended in patients with severe hepatic impairment (see section 5.2). It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B) (see sections 4.2 and 5.2). Patients with elevated liver enzymes ALT/AST > 2 x ULN or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials. Therefore Eliquis should be used cautiously in this population (see section 5.2). Prior to initiating Eliquis, liver function testing should be performed. Interaction with inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir). These medicinal products may increase apixaban exposure by 2-fold (see section 4.5) or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment). Interaction with inducers of both CYP3A4 and P-gp The concomitant use of Eliquis with strong CYP3A4 and P-gp inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital or St. John's Wort) may lead to a ~50% reduction in apixaban exposure. In a clinical study in atrial fibrillation patients, diminished efficacy and a higher risk of bleeding were observed with coadministration of apixaban with strong inducers of both CYP3A4 and P-gp compared with using apixaban alone. Strong inducers of both CYP3A4 and P-gp should be co-administered with caution (see section 4.5). Hip fracture surgery Apixaban has not been studied in clinical trials in patients undergoing hip fracture surgery to evaluate efficacy and safety in these patients. Therefore, it is not recommended in these patients. Laboratory parameters Clotting tests (e.g., PT, INR, and aPTT) are affected as expected by the mechanism of action of apixaban. Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability (see section 5.1). Information about excipients Eliquis contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. 4.5 Interaction with other medicinal products and other forms of interaction Inhibitors of CYP3A4 and P-gp Co-administration of apixaban with ketoconazole (400 mg once a day), a strong inhibitor of both CYP3A4 and P-gp, led to a 2-fold increase in mean apixaban AUC and a 1.6-fold increase in mean apixaban Cmax. The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see section 4.4). Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (eg. diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase apixaban plasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean apixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively. No dose adjustment for apixaban is required when co-administered with less potent inhibitors of CYP3A4 and/or P-gp. Inducers of CYP3A4 and P-gp Co-administration of apixaban with rifampicin, a strong inducer of both CYP3A4 and P-gp, led to an approximate 54% and 42% decrease in mean apixaban AUC and Cmax, respectively. The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine, phenobarbital or St. John's Wort) may also lead to reduced apixaban plasma concentrations. No dose adjustment for apixaban is required during concomitant therapy with such agents, however strong inducers of both CYP3A4 and P-gp should be co-administered with caution (see section 4.4). Anticoagulants, platelet aggregation inhibitors and NSAIDs Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3). After combined administration of enoxaparin (40 mg single dose) with apixaban (5 mg single dose), an additive effect on anti-Factor Xa activity was observed. Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was co-administered with ASA 325 mg once a day. Apixaban co-administered with clopidogrel (75 mg once a day) or with the combination of clopidogrel 75 mg and ASA 162 mg once daily in Phase 1 studies did not show a relevant increase in template bleeding time, or further inhibition of platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone. Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively. Corresponding increases in clotting tests were observed for apixaban. No changes were observed in the effect of naproxen on arachidonic acid-induced platelet aggregation and no clinically relevant prolongation of bleeding time was observed after concomitant administration of apixaban and naproxen. Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplatelet agents are co-administered with apixaban. Eliquis should be used with caution when co-administered with NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk. A significant increase in bleeding risk was reported with the triple combination of apixaban, ASA and clopidogrel in a clinical study in patients with acute coronary syndrome (see section 4.4). Agents associated with serious bleeding are not recommended concomitantly with Eliquis, such as: thrombolytic agents, GPIIb/IIIa receptor antagonists, thienopyridines (e.g., clopidogrel), dipyridamole, dextran and sulfinpyrazone. Other concomitant therapies No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was co-administered with atenolol or famotidine. Co-administration of apixaban 10 mg with atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban. Following administration of the two medicinal products together, mean apixaban AUC and Cmax were 15% and 18% lower than when administered alone. The administration of apixaban 10 mg with famotidine 40 mg had no effect on apixaban AUC or Cmax. Effect of apixaban on other medicinal products In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 μM) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 μM) at concentrations that are significantly greater than peak plasma concentrations observed in patients. Apixaban did not induce CYP1A2, CYP2B6, CYP3A4/5 at a concentration up to 20 μM. Therefore, apixaban is not expected to alter the metabolic clearance of coadministered drugs that are metabolized by these enzymes. Apixaban is not a significant inhibitor of P-gp. In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol. Digoxin: Co-administration of apixaban (20 mg once a day) and digoxin (0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax. Therefore, apixaban does not inhibit P-gp mediated substrate transport. Naproxen: Co-administration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, did not have any effect on the naproxen AUC or Cmax. Atenolol: Co-administration of a single dose of apixaban (10 mg) and atenolol (100 mg), a common beta-blocker, did not alter the pharmacokinetics of atenolol. Activated Charcoal Administration of activated charcoal reduces apixaban exposure (see section 4.9). 4.6 Fertility, pregnancy and lactation Pregnancy There are no data from the use of apixaban in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Apixaban is not recommended during pregnancy. Breast-feeding It is unknown whether apixaban or its metabolites are excreted in human milk. Available data in animals have shown excretion of apixaban in milk. In rat milk, a high milk to maternal plasma ratio (Cmax about 8, AUC about 30) was found, possibly due to active transport into the milk. A risk to newborns and infants cannot be excluded. A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy. Fertility Studies in animals dosed with apixaban have shown no effect on fertility (see section 5.3). 4.7 Effects on ability to drive and use machines Eliquis has no or negligible influence on the ability to drive and use machines. 4.8 Undesirable effects Summary of the safety profile The safety of apixaban has been investigated in 5,924 patients in VTEp studies and in 11,886 patients in NVAF studies, for an average total exposure of 20 days and 1.7 years respectively. In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced adverse reactions. Common adverse reactions were anaemia, haemorrhage, contusion, and nausea. Over the two phase III studies in NVAF, 24.4% (apixaban vs warfarin study) and 9.6% (apixaban vs aspirin study) of the patients treated with apixaban (5 mg or 2.5 mg) twice daily experienced adverse reactions. Common adverse reactions for apixaban were epistaxis, contusion, haematuria, haematoma, eye haemorrhage, and gastrointestinal haemorrhage. The overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in the apixaban vs warfarin study and was 9.6% in the apixaban vs aspirin study (see section 5.1). In the apixaban vs warfarin study the incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year. The incidence of ISTH major intraocular bleeding with apixaban was 0.18%/year. Tabulated list of adverse reactions Table 1 shows the adverse reactions ranked under headings of System Organ Class and frequency using the following convention: very common (≥1/10); common (≥1/100 to < 1/10); uncommon (≥1/1,000 to < 1/100); rare (≥1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data) for both VTEp and NVAF. Table 1
System Organ Class |
VTEp |
NVAF |
Blood and lymphatic system disorders |
Anaemia (including postoperative and haemorrhagic anaemia, and respective laboratory parameters) |
Common |
- |
Thrombocytopenia (including platelet count decreases) |
Uncommon |
- |
Immune system disorders |
Hypersensitivity (including skin rash, anaphylactic reaction and allergic edema) |
- |
Uncommon |
Hypersensitivity |
Rare |
- |
Nervous system disorders |
Brain haemorrhage, other intracranial or intraspinal haemorrhage (including subdural haematoma, subarachnoid haemorrhage, and spinal haematoma) |
- |
Uncommon |
Eye disorders |
Eye haemorrhage (including conjunctival haemorrhage) |
- |
Common |
Ocular haemorrhage (including conjunctival haemorrhage) |
Rare |
- |
Vascular disorders |
Haemorrhage (including haematoma, and vaginal and urethral haemorrhage) |
Common |
- |
Other haemorrhage, haematoma |
- |
Common |
Hypotension (including procedural hypotension) |
Uncommon |
- |
Intra-abdominal haemorrhage |
- |
Uncommon |
Respiratory, thoracic and mediastinal disorders |
Epistaxis |
Uncommon |
Common |
Haemoptysis |
Rare |
Uncommon |
Respiratory tract haemorrhage (including pulmonary alveolar haemorrhage, laryngeal haemorrhage and pharyngeal haemorrhage) |
- |
Rare |
Gastrointestinal disorders |
Nausea |
Common |
- |
Gastrointestinal haemorrhage (including haematemesis and melaena). rectal haemorrhage, gingival bleeding |
- |
Common |
Gastrointestinal haemorrhage (including haematemesis and melaena), haematochezia |
Uncommon |
- |
Haemorrhoidal haemorrhage, haematochezia, mouth haemorrhage |
- |
Uncommon |
Rectal haemorrhage, gingival bleeding |
Rare |
- |
Retroperitoneal haemorrhage |
- |
Rare |
Hepatobiliary disorders |
Transaminases increased (including alanine aminotransferase increased and alanine aminotransferase abnormal), aspartate aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, blood alkaline phosphatase increased, blood bilirubin increased |
Uncommon |
- |
Musculoskeletal and connective tissue disorders |
Muscle haemorrhage |
Rare |
- |
Renal and urinary disorders |
Haematuria |
- |
Common |
Haematuria (including respective laboratory parameters) |
Uncommon |
- |
Reproductive system and breast disorders |
Abnormal vaginal haemorrhage, urogenital haemorrhage |
- |
Uncommon |
General disorders and administration site conditions |
Application site bleeding |
- |
Uncommon |
Investigations |
Occult blood positive |
- |
Uncommon |
Injury, poisoning and procedural complications |
Contusion |
Common |
Common |
Post procedural haemorrhage (including post procedural haematoma, wound haemorrhage, vessel puncture site haematoma and catheter site haemorrhage) wound secretion, incision site haemorrhage (including incision site haematoma), operative haemorrhage |
Uncommon |
- |
Traumatic haemorrhage, post procedural haemorrhage, incision site haemorrhage |
- |
Uncommon | The use of Eliquis may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in posthaemorrhagic anaemia. The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding (see section 4.4 and section 5.1). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via: United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard Ireland Pharmacovigilance Section Irish Medicines Board Kevin O'Malley House Earlsfort Centre Earlsfort Terrace IRL - Dublin 2 Tel: +353 1 6764971 Fax: +353 1 6762517 Website: www.imb.ie e-mail: imbpharmacovigilance@imb.ie 4.9 Overdose There is no antidote to Eliquis. Overdose of apixaban may result in a higher risk of bleeding. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. The initiation of appropriate treatment, e.g., surgical haemostasis or the transfusion of fresh frozen plasma should be considered. In controlled clinical trials, orally-administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily (bid) for 7 days or 50 mg once daily (OD) for 3 days) had no clinically relevant adverse effects. In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively, and had no impact on Cmax. Mean half-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3 hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours after apixaban. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion. If life-threatening bleeding cannot be controlled by the above measures, administration of recombinant factor VIIa may be considered. However, there is currently no experience with the use of recombinant factor VIIa in individuals receiving apixaban. Re-dosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation of a coagulation expert should be considered in case of major bleedings. Haemodialysis decreased apixaban AUC by 14% in subjects with end stage renal disease, when a single dose of apixaban 5 mg was administered orally. Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose. 5. Pharmacological properties 5.1 Pharmacodynamic properties Pharmacotherapeutic group: direct factor Xa inhibitors, ATC code: B01AF02 Mechanism of action Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development. Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis. Pharmacodynamic effects The pharmacodynamic effects of apixaban are reflective of the mechanism of action (FXa inhibition). As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability. They are not recommended to assess the pharmacodynamic effects of apixaban. Apixaban also demonstrates anti-FXa activity as evident by reduction in Factor Xa enzyme activity in multiple commercial anti-FXa kits, however results differ across kits. Data from clinical trials are only available for the Rotachrom Heparin chromogenic assay. Anti-FXa activity exhibits a close direct linear relationship with apixaban plasma concentration, reaching maximum values at the time of apixaban peak plasma concentrations. The relationship between apixaban plasma concentration and anti-FXa activity is linear over a wide dose range of apixaban. Table 2 below shows the predicted steady state exposure and anti-Factor Xa activity for each indication. In patients taking apixaban for the prevention of VTE following hip or knee replacement surgery, the results demonstrate a less than 1.6-fold fluctuation in peak-to-trough levels. In nonvalvular atrial fibrillation patients taking apixaban for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels.
Table 2: Predicted Apixaban Steady-state Exposure and Anti-Xa Activity |
|
Apix.
Cmax (ng/mL) |
Apix.
Cmin (ng/mL) |
Apix. Anti-Xa Activity Max (IU/mL) |
Apix. Anti-Xa Activity Min (IU/mL) |
|
Median [5th, 95th Percentile] |
Prevention of VTE: elective hip or knee replacement surgery |
2.5 mg BID |
77 [41, 146] |
51 [23, 109] |
1.3 [0.67, 2.4] |
0.84 [0.37, 1.8] |
Prevention of stroke and systemic embolism: NVAF |
2.5 mg BID* |
123 [69, 221] |
79 [34, 162] |
1.8 [1.0, 3.3] |
1.2 [0.51, 2.4] |
5 mg BID |
171 [91, 321] |
103 [41, 230] |
2.6 [1.4, 4.8] |
1.5 [0.61, 3.4] | * Dose adjusted population based on 2 of 3 dose reduction criteria in the ARISTOTLE study. Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery. Clinical efficacy and safety Prevention of VTE (VTEp): elective hip or knee replacement surgery The apixaban clinical program was designed to demonstrate the efficacy and safety of apixaban for the prevention of VTE in a broad range of adult patients undergoing elective hip or knee replacement. A total of 8,464 patients were randomized in two pivotal, double-blind, multi-national studies, comparing apixaban 2.5 mg given orally twice daily (4,236 patients) or enoxaparin 40 mg once daily (4,228 patients). Included in this total were 1,262 patients (618 in the apixaban group) of age 75 or older, 1,004 patients (499 in the apixaban group) with low body weight (≤ 60 kg), 1,495 patients (743 in the apixaban group) with BMI ≥ 33 kg/m2, and 415 patients (203 in the apixaban group) with moderate renal impairment. The ADVANCE-3 study included 5,407 patients undergoing elective hip replacement, and the ADVANCE-2 study included 3,057 patients undergoing elective knee replacement. Subjects received either apixaban 2.5 mg given orally twice daily (po bid) or enoxaparin 40 mg administered subcutaneously once daily (sc od). The first dose of apixaban was given 12 to 24 hours post-surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery. Both apixaban and enoxaparin were given for 32-38 days in the ADVANCE-3 study and for 10-14 days in the ADVANCE-2 study. Based on patient medical history in the studied population of ADVANCE-3 and ADVANCE-2 (8,464 patients), 46% had hypertension, 10% had hyperlipidemia, 9% had diabetes, and 8% had coronary artery disease. Apixaban demonstrated a statistically superior reduction in the primary endpoint, a composite of all VTE/all cause death, and in the Major VTE endpoint, a composite of proximal DVT, non-fatal PE, and VTE-related death, compared to enoxaparin in both elective hip or knee replacement surgery (see Table 3). Table 3: Efficacy results from pivotal phase III studies
Study |
ADVANCE-3 (hip) |
ADVANCE-2 (knee) |
Study treatment
Dose
Duration of treatment |
Apixaban
2.5 mg po bid
35 ± 3 d |
Enoxaparin
40 mg sc od
35 ± 3 d |
p-value |
Apixaban
2.5 mg po bid
12 ± 2 d |
Enoxaparin
40 mg sc od
12 ± 2 d |
p-value |
Total VTE/all-cause death |
Number of events/subjects
Event Rate |
27/1949
1.39% |
74/1917
3.86% |
<0.0001 |
147/976
15.06% |
243/997
24.37% |
<0.0001 |
Relative Risk
95% CI |
0.36
(0.22, 0.54) |
|
0.62
(0.51, 0.74) |
|
Major VTE |
Number of events/subjects
Event Rate |
10/2199
0.45% |
25/2195
1.14% |
0.0107 |
13/1195
1.09% |
26/1199
2.17% |
0.0373 |
Relative Risk
95% CI |
0.40
(0.15, 0.80) |
|
0.50
(0.26, 0.97) |
| The safety endpoints of major bleeding, the composite of major and clinically relevant non-major (CRNM) bleeding, and all bleeding showed similar rates for patients treated with apixaban 2.5 mg compared with enoxaparin 40 mg (see Table 4). All the bleeding criteria included surgical site bleeding. Table 4: Bleeding results from pivotal phase III studies*
ADVANCE-3 |
ADVANCE-2 |
|
Apixaban
2.5 mg po bid
35 ± 3 d |
Enoxaparin
40 mg sc od
35 ± 3 d |
Apixaban
2.5 mg po bid
12 ± 2 d |
Enoxaparin
40 mg sc od
12 ± 2 d |
All treated |
n = 2673 |
n = 2659 |
n = 1501 |
n = 1508 |
Treatment Period 1 |
Major |
22 (0.8%) |
18 (0.7%) |
9 (0.6%) |
14 (0.9%) |
Fatal |
0 |
0 |
0 |
0 |
Major + CRNM |
129 (4.8%) |
134 (5.0%) |
53 (3.5%) |
72 (4.8%) |
All |
313 (11.7%) |
334 (12.6%) |
104 (6.9%) |
126 (8.4%) |
Post-surgery treatment period 2 |
Major |
9 (0.3%) |
11 (0.4%) |
4 (0.3%) |
9 (0.6%) |
Fatal |
0 |
0 |
0 |
0 |
Major + CRNM |
96 (3.6%) |
115 (4.3%) |
41 (2.7%) |
56 (3.7%) |
All |
261 (9.8%) |
293 (11.0%) |
89 (5.9%) |
103 (6.8%) | * All the bleeding criteria included surgical site bleeding 1 Includes events occurring after first dose of enoxaparin (pre-surgery) 2 Includes events occurring after first dose of apixaban (post-surgery) The overall incidences of adverse reactions of bleeding, anaemia and abnormalities of transaminases (e.g., alanine aminotransferase levels) were numerically lower in patients on apixaban compared to enoxaparin in the phase II and phase III studies in elective hip and knee replacement surgery. In the knee replacement surgery study during the intended treatment period, in the apixaban arm 4 cases of PE were diagnosed against no cases in the enoxaparin arm. No explanation can be given to this higher number of PE. Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) A total of 23,799 patients were randomised in the clinical program (ARISTOTLE: apixaban versus warfarin, AVERROES: apixaban versus ASA) including 11,927 randomised to apixaban. The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more additional risk factors, such as: • prior stroke or transient ischaemic attack (TIA) • age ≥ 75 years • hypertension • diabetes mellitus • symptomatic heart failure (NYHA Class ≥ II) ARISTOTLE STUDY In the ARISTOTLE study a total of 18,201 patients were randomized to double-blind treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [4.7%], see section 4.2) or warfarin (target INR range 2.0-3.0), patients were exposed to study drug for a mean of 20 months. The mean age was 69.1 years, the mean CHADS2 score was 2.1 and 18.9 % of patients had prior stroke or TIA. In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 5) compared with warfarin. Table 5: Efficacy Outcomes in Patients with Atrial Fibrillation in the ARISTOTLE Study
Apixaban
N=9120
n (%/yr) |
Warfarin
N=9081
n (%/yr) |
Hazard Ratio
(95% CI) |
p-value |
Stroke or systemic embolism |
212 (1.27) |
265 (1.60) |
0.79 (0.66, 0.95) |
0.0114 |
Stroke |
|
|
|
|
Ischaemic or unspecified |
162 (0.97) |
175 (1.05) |
0.92 (0.74, 1.13) |
|
Haemorrhagic |
40 (0.24) |
78 (0.47) |
0.51 (0.35, 0.75) |
|
Systemic embolism |
15 (0.09) |
17 (0.10) |
0.87 (0.44, 1.75) | For patients randomized to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%. Apixaban showed a reduction of stroke and systemic embolism compared to warfarin across the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% CI, 0.38, 1.40). Key secondary endpoints of major bleeding and all cause death were tested in a pre-specified hierarchical testing strategy to control the overall type 1 error in the trial. Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 6). With improving monitoring of INR the observed benefits of apixaban compared to warfarin regarding all cause death diminish. Table 6: Secondary endpoints in Patients with Atrial Fibrillation in the ARISTOTLE Study
Apixaban
N = 9088
n (%/year) |
Warfarin
N = 9052
n (%/year) |
Hazard Ratio
(95% CI) |
p-value |
Bleeding Outcomes |
Major* |
327 (2.13) |
462 (3.09) |
0.69 (0.60, 0.80) |
< 0.0001 |
Fatal |
10 (0.06) |
37 (0.24) |
|
|
Intracranial |
52 (0.33) |
122 (0.80) |
|
|
Major + CRNM |
613 (4.07) |
877 (6.01) |
0.68 (0.61, 0.75) |
< 0.0001 |
All |
2356 (18.1) |
3060 (25.8) |
0.71 (0.68, 0.75) |
< 0.0001 |
Other Endpoints |
All-cause death |
603 (3.52) |
669 (3.94) |
0.89 (0.80, 1.00) |
0.0465 |
Myocardial infarction |
90 (0.53) |
102 (0.61) |
0.88 (0.66, 1.17) | *Major bleeding defined per International Society on Thrombosis and Haemostasis (ISTH) criteria. The overall discontinuation rate due to adverse reactions was 1.8% for apixaban and 2.6% for warfarin in the ARISTOTLE study. The efficacy results for prespecified subgroups, including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the primary efficacy results for the overall population studied in the trial. The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin. The major bleeding results for prespecified subgroups including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the results for the overall population studied in the trial. AVERROES STUDY In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomized to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA. ASA was given at a once daily dose of 81 mg (64%), 162 (26.9%), 243 (2.1%), or 324 mg (6.6%) at the discretion of the investigator. Patients were exposed to study drug for a mean of 14 months. The mean age was 69.9 years, the mean CHADS2 score was 2.0 and 13.6% of patients had prior stroke or TIA. Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medication instruction (15.0%), and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%). AVERROES was stopped early based on a recommendation by the independent Data Monitoring Committee due to clear evidence of reduction of stroke and systemic embolism with an acceptable safety profile. The overall discontinuation rate due to adverse reactions was 1.5% for apixaban and 1.3% for ASA in the AVERROES study. In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 7) compared to ASA. Table 7: Key Efficacy Outcomes in Patients with Atrial Fibrillation in the AVERROES Study
Apixaban
N = 2807
n (%/year) |
ASA
N = 2791
n (%/year) |
Hazard Ratio
(95% CI) |
p-value |
Stroke or systemic embolism* |
51 (1.62) |
113 (3.63) |
0.45 (0.32, 0.62) |
< 0.0001 |
Stroke |
|
|
|
|
Ischaemic or unspecified |
43 (1.37) |
97 (3.11) |
0.44 (0.31, 0.63) |
|
Haemorrhagic |
6 (0.19) |
9 (0.28) |
0.67 (0.24, 1.88) |
|
Systemic embolism |
2 (0.06) |
13 (0.41) |
0.15 (0.03, 0.68) |
|
Stroke, systemic embolism, MI, or vascular death*† |
132 (4.21) |
197 (6.35) |
0.66 (0.53, 0.83) |
0.003 |
Myocardial infarction |
24 (0.76) |
28 (0.89) |
0.86 (0.50, 1.48) |
|
Vascular Death |
84 (2.65) |
96 (3.03) |
0.87 (0.65, 1.17) |
|
All-cause death† |
111 (3.51) |
140 (4.42) |
0.79 (0.62, 1.02) |
0.068 | * Assessed by sequential testing strategy designed to control the overall type I error in the trial. † Secondary endpoint. There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 8). Table 8: Bleeding Events in Patients with Atrial Fibrillation in the AVERROES Study
Apixaban
N = 2798
n(%/year) |
ASA
N = 2780
n (%/year) |
Hazard Ratio (95%CI) |
p-value |
Major* |
45 (1.41) |
29 (0.92) |
1.54 (0.96, 2.45) |
0.0716 |
Fatal, n |
5 (0.16) |
5 (0.16) |
|
|
Intracranial, n |
11 (0.34) |
11 (0.35) |
|
|
Major + CRNM |
140 (4.46) |
101 (3.24) |
1.38 (1.07, 1.78) |
0.0144 |
All |
325 (10.85) |
250 (8.32) |
1.30 (1.10, 1.53) |
0.0017 | *Major bleeding defined per International Society on Thrombosis ad Haemostasis (ISTH) criteria. Paediatric population The European Medicines Agency has deferred the obligation to submit the results of studies with Eliquis in one or more subsets of the paediatric population in venous and arterial embolism and thrombosis (see section 4.2 for information on paediatric use). 5.2 Pharmacokinetic properties Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Apixaban is rapidly absorbed with maximum concentrations (Cmax) appearing 3 to 4 hours after tablet intake. Intake with food does not affect apixaban AUC or Cmax at the 10 mg dose. Apixaban can be taken with or without food. Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg. At doses ≥ 25 mg apixaban displays dissolution limited absorption with decreased bioavailability. Apixaban exposure parameters exhibit low to moderate variability reflected by a within-subject and inter-subject variability of ~20% CV and ~30% CV, respectively. Distribution Plasma protein binding in humans is approximately 87%. The volume of distribution (Vss) is approximately 21 litres. Biotransformation and elimination Apixaban has multiple routes of elimination. Of the administered apixaban dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces. Renal excretion of apixaban accounts for approximately 27% of total clearance. Additional contributions from biliary and direct intestinal excretion were observed in clinical and nonclinical studies, respectively. Apixaban has a total clearance of about 3.3 l/h and a half-life of approximately 12 hours. O-demethylation and hydroxylation at the 3-oxopiperidinyl moiety are the major sites of biotransformation. Apixaban is metabolized mainly via CYP3A4/5 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. Unchanged apixaban is the major drug-related component in human plasma with no active circulating metabolites present. Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP). Renal impairment There was no impact of impaired renal function on peak concentration of apixaban. There was an increase in apixaban exposure correlated to decrease in renal function, as assessed via measured creatinine clearance. In individuals with mild (creatinine clearance 51-80 ml/min), moderate (creatinine clearance 30-50 ml/min) and severe (creatinine clearance 15-29 ml/min) renal impairment, apixaban plasma concentrations (AUC) were increased 16, 29, and 44% respectively, compared to individuals with normal creatinine clearance. Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity. In subjects with end-stage renal disease (ESRD), the AUC of apixaban was increased by 36% when a single dose of apixaban 5 mg was administered immediately after haemodialysis, compared to that seen in subjects with normal renal function. Haemodialysis, started two hours after administration of a single dose of apixaban 5 mg, decreased apixaban AUC by 14% in these ESRD subjects, corresponding to an apixaban dialysis clearance of 18 mL/min. Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose. Hepatic impairment In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment (Child-Pugh B score 7 (n = 6) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment. Changes in anti-Factor Xa activity and INR were comparable between subjects with mild to moderate hepatic impairment and healthy subjects. Elderly Elderly patients (above 65 years) exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 32% higher and no difference in Cmax. Gender Exposure to apixaban was approximately 18% higher in females than in males. Ethnic origin and race The results across phase 1 studies showed no discernible difference in apixaban pharmacokinetics between White/Caucasian, Asian and Black/African American subjects. Findings from a population pharmacokinetic analysis in patients who received apixaban were generally consistent with the phase 1 results. Body weight Compared to apixaban exposure in subjects with body weight of 65 to 85 kg, body weight > 120 kg was associated with approximately 30% lower exposure and body weight < 50 kg was associated with approximately 30% higher exposure. Pharmacokinetic/pharmacodynamic relationship The pharmacokinetic /pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 – 50 mg). The relationship between apixaban plasma concentration and anti-factor Xa activity was best described by a linear model. The PK/PD relationship observed in patients was consistent with that established in healthy subjects. 5.3 Preclinical safety data Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, fertility and embryo-foetal development and juvenile toxicity. The major observed effects in the repeated dose toxicity studies were those related to the pharmacodynamic action of apixaban on blood coagulation parameters. In the toxicity studies little to no increase of bleeding tendency was found. However, since this may be due to a lower sensitivity of the non-clinical species compared to humans, this result should be interpreted with caution when extrapolating to humans. 6. Pharmaceutical particulars 6.1 List of excipients Tablet core: Anhydrous lactose Microcrystalline cellulose (E460) Croscarmellose sodium Sodium laurilsulfate Magnesium stearate (E470b) Film coat: Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Triacetin (E1518) Yellow iron oxide (E172) 6.2 Incompatibilities Not applicable. 6.3 Shelf life 3 years 6.4 Special precautions for storage This medicinal product does not require any special storage condition. 6.5 Nature and contents of container Alu-PVC/PVdC blisters. Cartons of 10, 20, 60, 168 and 200 film-coated tablets. Alu PVC/PVdC perforated unit dose blisters of 60x1 and 100x1 film-coated tablets. Not all pack sizes may be marketed. 6.6 Special precautions for disposal and other handling No special requirements. 7. Marketing authorisation holder Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH United Kingdom 8. Marketing authorisation number(s) EU/1/11/691/001 EU/1/11/691/002 EU/1/11/691/003 EU/1/11/691/004 EU/1/11/691/005 EU/1/11/691/013 EU/1/11/691/015 9. Date of first authorisation/renewal of the authorisation Date of first authorisation: 18 May 2011 10. Date of revision of the text 25 April 2014 Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu |